Akash Mourya | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Mr. Akash Mourya | Health and Medicine Advances | Best Researcher Award

PhD Scholar | National Institutes of Pharmaceutical Education and Research | India

Mr. Akash Mourya is a promising young pharmacologist specializing in pharmacology and toxicology, with a strong research focus on liver pathophysiology, hepatoprotective drug discovery, and molecular mechanisms underlying hepatic and pulmonary disorders. His ongoing Ph.D. work at NIPER Mohali builds on extensive preclinical and translational research conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, where he has developed expertise in animal models of liver diseases, hemodynamic studies, and hepatic cell culture systems. His research contributions have advanced understanding of non-alcoholic and alcoholic fatty liver diseases, hepatopulmonary and porto-pulmonary hypertension, and liver regeneration mechanisms. He has co-authored seven peer-reviewed publications in high-impact journals, including Journal of Hepatology, JHEP Reports, American Journal of Physiology–Gastrointestinal and Liver Physiology, npj Gut and Liver, ACS Omega, and Life Sciences. His work has collectively received 31 citations, 7 Documents, with an h-index of 3, reflecting growing recognition within the biomedical research community. In addition to journal articles, Mr. Akash Mourya has contributed two book chapters published by Springer Nature (2024) and Academic Press (2025), covering topics such as oxidative stress and pharmacological interventions in liver disease, and PPARγ signaling in diabetes. His research abstracts have been presented at prestigious international conferences, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). His work integrates pharmacological innovation, molecular biology, and experimental therapeutics, with emphasis on Ayurvedic formulations, CB2 receptor agonists, and novel siRNA nanoparticle delivery systems. Mr. Akash Mourya’s ongoing efforts contribute to translational R&D for liver protection and regeneration, aligning with India’s growing emphasis on integrative pharmacology and precision medicine.

Profiles: Scopus | Google Scholar | ResearchGate | PubMed 

Featured Publications

1. Baweja, S., Kumari, A., Negi, P., Tomar, A., Tripathi, D. M., Mourya, A. K., Rastogi, A., Subudhi, P. D., Thangariyal, S., Kumar, G., Kumar, J., Sood, A., Vashistha, C., Bihari, C., Maiwall, R., & Sarin, S. K. (2023). Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod. Journal of Hepatology, 79(1), 167–180.

2. Juneja, P., Rahman, S. N. R., Jakhar, D., Mourya, A. K., Tripathi, D. M., Kaur, I., Tiwari, V., & others. (2023). Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis. JHEP Reports, 5(10), 100816.

3. Biswas, S., Yadav, N., Juneja, P., Mourya, A. K., Kaur, S., Tripathi, D. M., & Chauhan, V. S. (2022). Conformationally restricted dipeptide-based nanoparticles for delivery of siRNA in experimental liver cirrhosis. ACS Omega, 7(41), 36811–36824.

4. Kaur, I., Juneja, P., Tiwari, R., Vasudevan, A., Mourya, A. K., Trauner, M., Sarin, S. K., & Tripathi, D. M. (2024). Secondary bile acids in portal blood contribute to liver regeneration in a rat model of partial hepatectomy. American Journal of Physiology – Gastrointestinal and Liver Physiology, 327(4), G645–G658.

5. Tripathi, D. M., Singh, P., Mourya, A. K., & Kaur, S. (2024). Oxidative medicine and novel pharmacological treatment approaches in liver disease. In Adaptation under stressful environments through biological adjustments and interventions (pp. 311–334). Springer Nature.

 

Bing Han | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Dr. Bing Han | Health and Medicine Advances | Best Researcher Award

Postdoctoral Researcher, The First Affiliated Hospital of Zhengzhou University, China

Dr. Bing Han, Professor at The First Affiliated Hospital of Zhengzhou University, China, is an accomplished medical scientist and clinician whose research bridges molecular biology, microbiome science and clinical gastroenterology. He earned his medical degree (M.D.) followed by postdoctoral research training focused on digestive disease mechanisms and microbial interactions, establishing a strong foundation in translational and precision medicine. His primary research interests center on the gut microbiota–host interaction, bile acid metabolism, intestinal inflammation and biomarker discovery for digestive disorders, with emerging interests in microbiome-based therapeutic interventions. Over his distinguished career, Dr. Bing Han has held academic and clinical roles at The First Affiliated Hospital of Zhengzhou University and collaborated with The First Affiliated Hospital of the University of Science and Technology of China, contributing to interdisciplinary advancements in medical research. His key scientific contributions include innovative studies on the mechanisms of fecal microbiota transplantation in improving inflammatory bowel disease (IBD) and the development of biomedical devices such as spinal positioning systems and femoral defect fixation stents. He has published 9 scientific documents, receiving 50 citations with an h-index of 5 and authored the academic book Frontiers of Tumor Research. Among his notable research supports are the China Postdoctoral Science Foundation Grant, National Natural Science Foundation of China Grant and the Guangxi Natural Science Foundation and Health Commission Projects of Guangxi Zhuang Autonomous Region. His professional engagements include serving as a Young Editorial Board Member for the Journal of Guangxi Medical University and membership in the Digestive Professional Committee of the Chinese Society of Pathophysiology and the Gut Microbiota Branch of the Chinese Society of Biophysics. Through his pioneering research on gut microbiota and digestive pathophysiology, Dr. Bing Han aims to revolutionize clinical diagnostics and therapeutics, promoting global health advancement and innovation in biomedical science.

Profile: Scopus | ORCID | ResearchGate

Featured Publications

1. Han, B., Tang, D., Zhu, H., et al. (2024). Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism regulating immunotherapy responses to anti-α4β7-integrin in Crohn’s disease. Gut Microbes, 16(1), 2310894.

2. Han, B., Li, C., Meng, H., et al. (2019). Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Bioscience Trends, 13(1), 10–22.

3. Han, B., Tang, D., Lv, X., et al. (2023). Comparative efficacy and safety of combination therapy with infliximab for Crohn’s disease: A systematic review and network meta-analysis. International Journal of Colorectal Disease, 38(1), 82.

4. Han, B., Shao, L., Li, C., et al. (2019). Surgery versus external beam radiation therapy for AJCC stage I hepatocellular carcinoma. Journal of BUON, 24(4), 1390–1401.

5. Han, B., Yao, H., Shao, L., et al. (2018). Selection of treatment modalities for hepatocellular carcinoma at stages T1 and T2: A preliminary analysis based on the Surveillance, Epidemiology, and End Results registry database. Journal of BUON, 23(3), 611–621.

 

Seema Kandalkar | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Ms. Seema Kandalkar | Health and Medicine Advances | Best Researcher Award

Student, Sanjivani College of Pharmaceutical Education and Research, Kopargaon (SPPU), India

Ms. Seema Kandalkar is a dedicated pharmaceutical researcher currently serving as an IPR Trainee at Trexo Global Pvt. Ltd, Nashik, and is affiliated with Sanjivani College of Pharmaceutical Education and Research (SPPU). She completed her M. Pharmacy in Pharmaceutics from Sanjivani College of Pharmaceutical Education and Research, Kopargaon, in 2025, following a B. Pharmacy from Pravara Rural Education Society College of Pharmacy (SPPU, 2023). Her research primarily focuses on formulation and development of innovative drug delivery systems, including probiotic and effervescent tablet formulations, with emerging interests in regulatory affairs and intellectual property rights. She has gained significant hands-on experience through her industrial projects and internships at Sci-Tech Efferceuticals (R&D), Sanpras Healthcare Pvt. Ltd., and Reve Pharma, where she honed practical skills in analytical techniques, GMP, stability studies, dissolution testing and drug delivery design. Among her key contributions, she successfully developed and evaluated a probiotic effervescent tablet during her M. Pharmacy project and has disseminated her findings via a review article accepted in Journal of Future Foods (ScienceDirect, IF 7.2), along with poster presentations at international conferences and participation in national-level research competitions. Her work has been recognized for its academic rigor and innovative approach in pharmaceutical sciences, earning accolades through national seminars and competitive workshops. Professionally, she is skilled in Microsoft Office Suite, BioRender and Zotero and actively participates in scientific workshops and seminars. Author metrics for Ms. Seema Kandalkar include 1 published document with citation potential, currently reflecting initial scholarly impact. Her work contributes to advancing formulation science, promoting effective healthcare solutions, and strengthening pharmaceutical innovation and intellectual property awareness. Her vision encompasses enhancing patient-centric drug delivery, fostering regulatory excellence and contributing to global pharmaceutical research standards. With her blend of academic excellence, industrial exposure and research innovation, Ms. Seema Kandalkar is well-positioned to make significant contributions to pharmaceutical sciences and healthcare innovation internationally.

Profile: ORCID | ResearchGate | LinkedIn

Featured Publications

1. Kandalkar, S. T., Shendge, R. S., & Lohakare, O. K. (2025). Unveiling the therapeutic potential of probiotics: A review. Journal of Future Foods. Advance online publication.

 

Priyanka Garg | Health and Medicine | Best Researcher Award

Published on by New Scientists

Ms. Priyanka Garg | Health and Medicine | Best Researcher Award

Assistant Professor, Lovely Professional University, India

Ms. Priyanka Garg is currently serving as an Assistant Professor at the School of Pharmaceutical Sciences, Lovely Professional University (LPU), Punjab, India, where she contributes actively to academic instruction, clinical research, and student mentorship. She holds an M.Pharm in Pharmacy Practice (2022) and a B.Pharm (2020), both from Lovely Professional University, with specialization in pharmacotherapy, pharmacovigilance, and patient-centered care. Her primary research interests encompass pharmacogenomics, clinical pharmacology, women’s health, chronic disease management, and the role of gut microbiota in metabolic disorders, with emerging work focusing on personalized medicine for PCOS and Ehlers-Danlos Syndrome. Professionally, she has served at LPU since January 2023 and previously trained at Shiva Biogenetic Pharmaceuticals Pvt. Ltd. and Doaba Hospital Pvt. Ltd., where she gained practical expertise in manufacturing, IPQC, patient monitoring, and clinical data analysis. Her key contributions include two granted copyrights—“Laboratory and Clinical Result for Polycystic Ovary Syndrome” (2024) and “Clinical Findings for Ehlers-Danlos Syndrome” (2025)—and several impactful presentations at national and international conferences such as SHE-SCIENCE 2025 and the International Conference of Pharmacy series. She has published indexed research in reputed journals including Obesity Medicine and Human Gene. Her scholarly influence is reflected through her author metrics: 3 documents, 25 citations and an h-index of 2. Among her awards and honors, she was recognized for her publication on Type 2 Diabetes Mellitus and Quality of Life (2022) and received accolades for her leadership roles as Faculty Coordinator and Organizing Committee Member for major scientific events at LPU. Additionally, she serves as a Reviewer for the Population Medicine Journal and engages in academic outreach, environmental awareness, and student development programs. Through her interdisciplinary research and commitment to education, Ms. Priyanka Garg aims to advance pharmacogenomics-based therapeutic strategies and promote evidence-driven healthcare innovation that bridges scientific discovery with societal impact.

Profile: Scopus | ORCID | ResearchGate

Featured Publications

1. Garg, P., & Yanadaiah, P. (2025). Assessment of quality of life among type 2 diabetes mellitus and hypertensive patients in Punjab region: A WHOQoL-BREF based hospital study. Obesity Medicine, 58, 100651.

2. Garg, P., Jallepalli, V. R., & Verma, S. (2024). Unravelling the CXCL12/CXCR4 axis in breast cancer: Insights into metastasis, microenvironment interactions, and therapeutic opportunities. Human Gene, 40, 201272.

3. Garg, P., & Duggal, N. (2022). Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed–A review. Obesity Medicine, 35, 100459.

 

Yiling Hou | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Dr. Yiling Hou | Health and Medicine | Best Researcher Award

Professor, China West Normal University, China

Prof. Dr. Yiling Hou is a distinguished scientist and Professor at the College of Life Sciences, China West Normal University, recognized as a reserve candidate for academic and technological leadership in Sichuan Province and an overseas high-level talent. She earned her Bachelor of Science in Pharmacy (2005) and Master of Science in Medicinal Chemistry (2008) from Sichuan University, followed by a Doctor of Science in Biochemistry and Molecular Biology (2011) from Sichuan Agricultural University and further enhanced her expertise as a visiting scholar at the Perelman School of Medicine, University of Pennsylvania (2017–2018). Beginning her career as a Teaching Assistant in 2008, she advanced to Lecturer in 2011, Associate Professor in 2011 and full Professor in 2016, also serving as Program Director for Biotechnology (2013–2020) and currently as Deputy Director of the Sichuan Collaborative Innovation Center for Tissue Repair Materials Engineering Technology. Her research focuses on the isolation, purification, structural identification and biological activity of fungal polysaccharides, alongside tumor cell kinetics, spindle dynamics during mitosis, meiosis and the molecular mechanisms underlying cancer progression. Skilled in structural identification, molecular medicine, apoptosis analysis and advanced biopharmaceutical techniques, she has published 104 Scopus-indexed papers with 787 citations and an h-index of 16, reflecting her growing international impact. Prof. Dr. Yiling Hou is an active Councilor of the Sichuan Provincial Microbiology Society and the Sichuan Provincial Youth Federation, highlighting her commitment to scientific community leadership and youth engagement. Honored as an emerging academic leader in Sichuan Province, she continues to guide students and collaborative projects that bridge traditional pharmacology and modern oncology. With her strong publication record, leadership roles and global collaborations, Prof. Dr. Yiling Hou is poised to make transformative contributions to cancer research and molecular therapeutics, advancing biomedical science and inspiring future generations of researchers.

Profile: Scopus | ResearchGate | Sci Profiles | Scilit

Featured Publications

1. Wang, Y., Lu, R., Ding, X., You, Y., Lin, Y., Hou, Y., & Xia, Y. (2025). Structure identification and in vitro immunomodulatory activities of polysaccharide AHL26-P from Arachis hypogaea (Tianfu 26) leaves. Results in Chemistry, 18, 102724.

2. Sun, Z.-A., Zhao, N., Zheng, L., Pan, F., Ding, X., & Hou, Y. (2025, June 26). Comparative studies on the structure and biological activities of two new polysaccharides from Tricholoma flavovirens (TF-P) and Trametes versicolor (TV-P). Results in Chemistry. Advance online publication.

3. Liu, K., Sun, Z., Li, X., Qing, X., Yu, W., Liu, M., Ding, X., & Hou, Y. (2025). Structure characterization and biological activity of polysaccharides from Trametes sanguinea (TS-P) and wild Lentinus edodes (LE-P). Food Bioscience, 68, 106656.

4. Zhou, L., Ding, X., & Hou, Y. (2024). The structure characterization and biological activities of new polysaccharides from Armillariella tabescens (AT-P) and Tricholoma portentosum (TP-P). Results in Chemistry, 18, 4620–4633.

5. Yu, W., Yuan, R., Liu, M., Liu, K., Ding, X., & Hou, Y. (2024). Effects of rpl1001 gene deletion on cell division of fission yeast and its molecular mechanism. Current Issues in Molecular Biology, 46(3), 2576–2597.

 

Song-Wei Li | Medicine Advances | Best Researcher Award

Published on by New Scientists

Dr. Song-Wei Li | Medicine Advances | Best Researcher Award

Lecturer at School of medicine, Shanghai University, China.

Dr. Song-Wei Li is a lecturer at the School of Medicine, Shanghai University, and a marine natural product chemist specializing in secondary metabolites from marine organisms. He obtained his Ph.D. from Nanjing University of Chinese Medicine in 2021, with part of his training at the Shanghai Institute of Materia Medical under the mentorship of Prof. Yue-Wei Guo. With over 20 publications in internationally recognized journals, Dr. Li contributes significantly to marine chemoecology and drug discovery, exploring structurally unique compounds with biological potential.

Publication Profile

Scopus

Orcid

Educational Details

  • Ph.D. in Marine Natural Product Chemistry, Nanjing University of Chinese Medicine, China (2021)

    • Joint training at Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  • M.Sc. in Pharmaceutical Chemistry, Nanchang University, China (2018)

  • B.Sc. in Pharmacy, Nanchang University, China (2015)

Professional Experience

  • Lecturer, School of Medicine, Shanghai University, China (2023–Present)

  • Postdoctoral Researcher, College of Pharmaceutical Science, Zhejiang University of Technology, China (2021–2023)

  • Research Training, Chinese Academy of Sciences Shanghai Institute of Materia Medica (During Ph.D., under Prof. Yue-Wei Guo)

Research Interest

Dr. Li’s research centers on the discovery, structure elucidation, chemoecology, and bioactivity evaluation of secondary metabolites derived from marine benthic invertebrates—including molluscs, sponges, and coelenterates—as well as marine flora. His studies emphasize marine diterpenoids, polypropionates, and macrocyclic natural products with potential anti-tumoral, anti-inflammatory, and antibacterial activities. He also integrates quantum mechanical-NMR methods for stereochemical analysis and structural determination.

Author Metrics

Number of Peer-Reviewed Journal Articles: 9
Publication Years: 2018–2025
Total Journals Covered: 8 (including top-tier journals in organic chemistry and marine natural products)

Research Focus

  • Marine Natural Products Chemistry: Focus on isolation and structural elucidation of unique diterpenoids and polypropionates from South China Sea marine organisms (soft corals, mollusks, sponges).

  • Synthetic Organic Chemistry: Biomimetic synthesis and rearrangement studies.

  • NMR and Quantum Mechanical Analysis: Stereochemical analysis using computational and spectroscopic methods.

  • Bioactivity-Oriented Isolation: Emphasis on anti-inflammatory, anti-tumoral, and antibacterial compounds.

Top Noted Publication

  1. Title: Cembrane-type diterpenoids from the South China Sea soft coral Sarcophyton mililatensis
    Journal: Acta Pharmaceutica Sinica B, 2018, 8, 944-955
    DOI: 10.1016/j.apsb.2018.06.004
    Authors: Song-Wei Li, Fei Ye, Zheng-Dan Zhu, Hui Huang, Shui-Chun Mao, Yue-Wei Guo
    Abstract: This study describes the isolation and structural characterization of cembrane-type diterpenoids from the soft coral Sarcophyton mililatensis found in the South China Sea. The compounds were analyzed for their potential biological activities, contributing to the understanding of their pharmacological properties.

  2. Title: Complex polypropionates from a South China Sea Photosynthetic Mollusk: Isolation and Biomimetic Synthesis Highlighting Novel Rearrangements
    Journal: Angewandte Chemie International Edition, 2020, 59, 12105-12112
    DOI: 10.1002/anie.202002261
    Authors: Qi-Hao Wu, Song-Wei Li, Heng Xu, Hong Wang, Pei Hu, Hao Zhang, Cheng Luo, Kai-Xian Chen, Bastien Nay, Yue-Wei Guo, Xu-Wen Li
    Abstract: The paper presents complex polypropionate compounds isolated from Placobranchus ocellatus, a photosynthetic mollusk. Biomimetic synthesis strategies were used to replicate the novel chemical rearrangements observed in these compounds. The study also discusses their potential biological activities and future applications.

  3. Title: Quantum Mechanica-NMR-aided configuration and conformation of two Unreported Macrocycles Isolated from the Soft Coral Lobophytum sp.: Energy Calculations versus Coupling Constants
    Journal: Organic Letters, 2020, 22, 4093-4096
    DOI: 10.1021/acs.orglett.0c01121
    Authors: Song-Wei Li, Cristina Cuadrado, Li-Gong Yao, Antonio Hernandez Daranas, Yue-Wei Guo
    Abstract: This paper discusses the structural characterization of two previously unreported macrocycles isolated from Lobophytum sp. using quantum mechanical NMR to determine the configuration and conformation. The study compares energy calculations with experimental coupling constants for structural validation.

  4. Title: Rare new bicyclic cembranoid ethers and a novel trihydroxy prenylated guaiane from the Xisha soft coral Lobophytum sp.
    Journal: Bioorganic Chemistry, 2020, 103, 104223
    DOI: 10.1016/j.bioorg.2020.104223
    Authors: Song-Wei Li, Cristina Cuadrado, Xia-Juan Huan, Li-Gong Yao, Ze-Hong Miao, Antonio Hernandez Daranas, Yue-Wei Guo
    Abstract: The paper reports the discovery of new bicyclic cembranoid ethers and a novel trihydroxy prenylated guaiane from Lobophytum sp. (a species of soft coral). The study provides in-depth structural analysis and evaluates their potential as bioactive compounds with anti-inflammatory properties.

  5. Title: Litosetoenins A-E, Diterpenoids from the soft coral Litophyton setoensis, Backbone-rearranged through Divergent Cyclization Achieved by Epoxide Reactivity Inversion
    Journal: The Journal of Organic Chemistry, 2021, 86, 11771-11781
    DOI: 10.1021/acs.jorgchem.0c03360
    Authors: Song-Wei Li, I. Wayan Mudianta, Cristina Cuadrado, Geng Li, Gede A. Yudasmara, Gede I. Setiabudi, Antonio Hernandez Daranas, Yue-Wei Guo
    Abstract: This study describes the isolation of diterpenoids (Litosetoenins A-E) from Litophyton setoensis and their unique structural features, which involve a divergent cyclization process facilitated by epoxide reactivity inversion. These compounds are analyzed for their chemical properties and potential pharmacological activities.

  6. Title: Ocellatuperoxides A-F, Uncommon Anti-Tumoral γ-Pyrone Peroxides from a Photosynthetic Mollusk Placobranchus ocellatus
    Journal: Marine Drugs, 2022, 20, 590
    DOI: 10.3390/md20090590
    Authors: Song-Wei Li, Qihao Wu, Heng Xu, Li-Gong Yao, Cheng Luo, Hong Wang, Hao Zhang, Xu-Wen Li, Yue-Wei Guo
    Abstract: This paper reports the isolation of Ocellatuperoxides A-F, γ-pyrone peroxides from Placobranchus ocellatus, a photosynthetic mollusk. These compounds exhibit anti-tumoral properties, and the study explores their potential therapeutic applications in cancer treatment.

  7. Title: Ocellatuspyrones A-G, new antibacterial polypropionates from the Chinese mollusk Placobranchus ocellatus
    Journal: Marine Life Science & Technology, 2023, 5, 373-386
    DOI: 10.1007/s42995-023-00042-2
    Authors: Song-Wei Li, Dan-Dan Yu, Ming-Zhi Su, Li-Gong Yao, Hong Wang, Xue-Ting Liu, Yue-Wei Guo
    Abstract: The paper describes the isolation of new antibacterial polypropionates (Ocellatuspyrones A-G) from Placobranchus ocellatus, examining their structure and antibacterial activities, providing insights into their potential use in treating bacterial infections.

  8. Title: Macrocyclic anti-inflammatory diterpenes from the South China Sea soft coral Sinularia erecta and their isolation by combined column chromatography
    Journal: Journal of Chromatography A, 2024, 1736, 465416
    DOI: 10.1016/j.chroma.2024.465416
    Authors: Song-Wei Li, Cristina Cuadrado, Jiao Liu, Heng Li, Wei Tang, Antonio Hernandez Daranas, Yue-Wei Guo
    Abstract: This study focuses on the isolation of macrocyclic anti-inflammatory diterpenes from Sinularia erecta, a soft coral from the South China Sea. Combined column chromatography was employed to isolate these compounds, which were then analyzed for their anti-inflammatory properties.

  9. Title: Uncommon Diterpenoids with Diverse Frameworks from the South China Sea Sponge Spongia officinalis and Their Anti-inflammatory Activities
    Journal: The Journal of Organic Chemistry, 2025, 90: 1950-1956
    DOI: 10.1021/acs.jorgchem.5b00123
    Authors: Song-Wei Li, Jiao Liu, Zi-Yi Liu, Yan Fu, Li-Gong Yao, Yu-Cheng Gu, Hai-Yan Zhang, Xu-Wen Li, Yue-Wei Guo
    Abstract: This research highlights the discovery of uncommon diterpenoids from the South China Sea sponge Spongia officinalis. The paper focuses on their diverse chemical frameworks and anti-inflammatory activities, with a focus on their potential therapeutic applications.

Conclusion

Dr. Song-Wei Li stands out as a highly deserving candidate for the Best Researcher Award due to his innovative research in marine natural products chemistry, his high-impact publications, and his unique interdisciplinary approach. His work has the potential to contribute significantly to drug discovery, particularly in areas of anti-inflammatory, anti-tumoral, and antibacterial therapies. With continued engagement in global scientific networks and an expansion of his research focus, Dr. Li is poised to make even greater contributions to science.